ACIR Strengthens Direct Pharmaceutical Supply to Central Asia

ACIR Southern Europe directly executes the supply of specialized gastroenterology medicines from Southern Europe to Central Asia, with shipments progressing according to schedule and under full operational control.

The operation covers production, quality assurance, documentation structuring, international logistics and regulatory adaptation to the legal frameworks of the destination countries. The supply is carried out under European standards, ensuring technical compliance, traceability and product stability throughout the entire chain.

Integrated execution and sector leadership

ACIR does not act as an intermediary, but as a project structurer and executor of international pharmaceutical initiatives. The current supply results from strategic planning, consolidated industrial agreements and an established operational network across Southern Europe and Central Asia.

Together with local partners, specific regulatory requirements, certifications and distribution conditions were validated to ensure efficient market entry. This integration capacity reduces risks, optimizes timelines and guarantees regulatory compliance from origin to destination.

Strategic impact and international positioning

The ongoing supply strengthens the positioning of European pharmaceutical production in Central Asia, in a context of growing demand for modern and accessible therapeutic solutions.

At the same time, countries in the region gain access to high-quality medicines manufactured under European standards and offered under competitive conditions. This model consolidates ACIR Southern Europe as a leading platform for the development and implementation of pharmaceutical projects between Southern Europe and Central Asia, generating industrial value, regulatory stability and new expansion opportunities in the sector.